scispace - formally typeset
H

Hagop S. Akiskal

Researcher at University of California, San Diego

Publications -  565
Citations -  53075

Hagop S. Akiskal is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Bipolar disorder & Temperament. The author has an hindex of 118, co-authored 565 publications receiving 50869 citations. Previous affiliations of Hagop S. Akiskal include Long Island University & University of Central Florida.

Papers
More filters
Journal ArticleDOI

Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication

TL;DR: This study presents the first prevalence estimates of the BPD spectrum in a probability sample of the United States, and finds subthreshold BPD is common, clinically significant, and underdetected in treatment settings.
Journal ArticleDOI

The long-term natural history of the weekly symptomatic status of bipolar I disorder.

TL;DR: Overall, the symptomatic structure is primarily depressive rather than manic, and subsyndromal and minor affective symptoms predominate, and the longitudinal weekly symptomatic course of BP-I is chronic.
Journal ArticleDOI

A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.

TL;DR: The longitudinal symptomatic course of BP-II is chronic and is dominated by depressive rather than hypomanic or cycling/mixed symptoms, involving primarily symptoms of minor and subsyndromal severity.
Journal ArticleDOI

Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders.

TL;DR: The present review did not consider cyclic, seasonal, irritable-dysphoric or otherwise impulse-ridden, intermittently explosive or agitated psychiatric conditions for which the bipolar connection is less established.
Journal ArticleDOI

Prevalence and Effects of Mood Disorders on Work Performance in a Nationally Representative Sample of U.S. Workers

TL;DR: Employer interest in workplace costs of mood disorders should be broadened beyond major depressive disorder to include bipolar disorder, and effectiveness trials are needed to study the return on employer investment of coordinated programs for workplace screening and treatment of bipolar disorder and major depressive Disorder.